Take Advantage Of The ‘Summer Dip’ With The FTSE 100, AstraZeneca plc & Vodafone Group plc

Now could be a great time to buy AstraZeneca plc (LON: AZN), Vodafone Group plc (LON: VOD) and the FTSE 100 (INDEXFTSE:UKX).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE100

‘Sell in May and don’t come back until St. Ledger’s day’ is a well-known saying in investing circles. Indeed, data from recent decades seems to back it up: the stock market rarely embarks on a sustained summer rally and usually falls between May and September. This has been the case in 2014, with the FTSE 100 falling by 1% over the last three months.

This means that the index is flat for the year so far, although it still appears to offer good value for money when compared to its American cousin, the S&P 500. While it trades on a price to earnings (P/E) ratio of 18.5, our FTSE 100 has a P/E of just 13.4. So, while many commentators have been getting excited about our ‘summer dip’ in terms of it being the beginning of a prolonged market correction, it could turn out to be little more than a mild, mundane and entirely predictable summer pullback.

Great Value

As a result of falls in the last few months, many top-notch FTSE 100 stocks are now even better value than they were in May. Two fine examples are AstraZeneca (LSE: AZN) and Vodafone (LSE: VOD). The former has fallen by 1.5% during the last three months, while the latter is down 7% over the same time period. This means that both companies now offer above-average yields of 4% and 5.7% respectively, which highlights their attractive valuations at current price levels.

Looking Ahead

However, there is a lot more to AstraZeneca and Vodafone that attractive prices. For example, AstraZeneca continues to make huge improvements to its drug pipeline and is gradually overcoming a sizeable patent cliff that has caused the company’s top and bottom lines to fall in recent years. Similarly, Vodafone is pursuing a sound strategy of buying undervalued assets in Europe. Although it may take many years for this strategy to come good, it looks set to put Vodafone on a long term path to strong growth and stability, which is great news for shareholders.

Certainly, the ‘summer dip’ may not yet be over. The FTSE 100, including AstraZeneca and Vodafone, may fall further. However, they seem to offer top notch value for money at present and appear to have bright futures. Indeed, with the UK economy continuing to pick up pace, and with interest rates looking less likely to move higher as a result of lower than expected inflation, a purple patch could be just around the corner. As a result, it could be worth coming back a little before St. Ledger’s day!

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female business analyst looking at a graph chart while working from home
Investing Articles

Is Avon Protection the best stock to buy in the FTSE All-Share index right now?

Here’s a stock I’m holding for recovery and growth from the FTSE All-Share index. Can it be crowned as the…

Read more »

Investing Articles

Down 8.5% this month, is the Aviva share price too attractive to ignore?

It’s time to look into Aviva and the insurance sector while the share price is pulling back from year-to-date highs.

Read more »

Investing Articles

Here’s where I see Vodafone’s share price ending 2024

Valued at just twice its earnings, is the Vodafone share price a bargain or value trap? Our writer explores where…

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

The Darktrace share price jumped 20% today. Here’s why!

After the Darktrace share price leapt by a fifth in early trading, our writer explains why -- and what it…

Read more »

Dividend Shares

850 shares in this dividend giant could make me £1.1k in passive income

Jon Smith flags up one dividend stock for passive income that has outperformed its sector over the course of the…

Read more »

Investing Articles

Unilever shares are flying! Time to buy at a 21% ‘discount’?

Unilever shares have been racing higher this week after a one-two punch of news from the company. Here’s whether I…

Read more »

artificial intelligence investing algorithms
Market Movers

The Microsoft share price surges after results. Is this the best AI stock to buy?

Jon Smith flags up the jump in the Microsoft share price after the latest results showed strong demand for AI…

Read more »

Google office headquarters
Investing Articles

A dividend announcement sends the Alphabet share price soaring. Here’s what investors need to know

As the Alphabet share price surges on the announcement of a dividend, Stephen Wright outlines what investors should really be…

Read more »